Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | ELANE | P08246 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 2/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | EBP | Q15125 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.43 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4802603 | 0.91 | MPO (0.60) | MPOELANEESR1ALDH1A1LMNA | |
| SCHEMBL14267917 | 0.87 | MPO (0.56) | MPOELANEMAPTACHENPC1 | |
| SCHEMBL23297253 | 0.86 | MPO (0.50) | MPOELANEESR1EBPSIGMAR1 | |
| SCHEMBL31414398 | 0.84 | CYP3A4 (0.58) | MPOELANEPTPN1ESR1MIF | |
| SCHEMBL3785482 | 0.82 | MPO (0.55) | MPOELANEEBPSIGMAR1MAPT | |
| SCHEMBL7633335 | 0.82 | MPO (0.51) | MPOELANEMIFMAPTSMN1; SMN2 | |
| SCHEMBL6789105 | 0.81 | PTPN1 (0.46) | MPOELANEPTPN1MAPTBACE1 | |
| SCHEMBL7633012 | 0.81 | MPO (0.54) | MPOELANEMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL8268146 | 0.81 | HTR1A (0.48) | MPOELANEMAPTNPC1RAB9A | |
| SCHEMBL23740183 | 0.80 | MAOB (0.56) | MAPTSMN1; SMN2NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774060-B2 | Oxone-aceton mediated metal free preparation of syn-diols | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-09-15 | — | — | US | disclosed |
| US-20160168114-A1 | Oxone-Aceton Mediated Metal Free Preparation of Syn-Diols | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-06-16 | — | — | US | disclosed |
| WO-2014207766-A1 | OXONE-ACETONE MEDIATED METAL FREE PREPARATION OF SYN-DIOLS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-12-31 | — | — | WO | disclosed |
| EP-1076644-B1 | N-SUBSTITUTED AMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2004-06-23 | — | — | EP | disclosed |
| EP-1076644-A1 | N-SUBSTITUTED AMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| US-6140354-A | FOR TREATMENT OF DISORDERS OR DISEASE STATES CAUSED BY EATING DISORDERS, OBESITY, BULIMIA NERVOSA, DIABETES, HYPERTENSION, MEMORY LOSS, EPILEPTIC SEIZURES, MIGRAINE, SLEEP DISTURBANCES, PAIN, SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| WO-1999055667-A1 | N-SUBSTITUTED AMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168114-A1 | Oxone-Aceton Mediated Metal Free Preparation of Syn-Diols | SQLE, OXER1, OXA1L | MPO 1767/4885ELANE 4195/4885PTPN1 4743/4885 |
| US-10774060-B2 | Oxone-aceton mediated metal free preparation of syn-diols | SQLE, OXER1, OXA1L | MPO 1767/4885ELANE 4195/4885PTPN1 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.